PUBLICATION

Global Business Reports

AUTHORS

Neha Premjee, Alice Pascoletti, Karl Reilly, Jan Schmidt-Whitley

India Pharmaceuticals 2015

December 12, 2014

India, the largest democracy and the tenth largest economy in the world, has seen growth rates over the last decade that many of its Western counterparts would envy. In no other industry is India’s recent growth more apparent than in pharmaceuticals. With the market estimated to have been at $6 billion in 2005, a threefold increase was seen in just seven years, as it expanded to $18 billion in 2012. India now accounts for approximately 1.4% of the global pharmaceutical industry in value and 10% in volume. McKinsey & Company projects that it will reach $45 billion by 2020.

This growth has been driven largely by the manufacture of active pharmaceutical ingredients (APIs), but the industry will need to evolve to maintain its growth. With a large number of drugs coming off patent in the coming years, including $90 billion in 2015, and becoming available to international players, it is expected that more Indian companies will have income to start increasing their investment in research and development (R&D). Though the recent wave of sanctions filed by the U.S. FDA against major Indian companies for inadequacies in their quality control has raised concerns, the past record of the Indian pharmaceuticals industry indicates that it will likely evolve and flourish in the coming years.

 

Featuring exclusive interviews with:

Aurobindo – N. Govindarajan, Managing Director
Biocon – Kiran Mazumdar-Shaw, Chairperson and Managing Director
Cipla Ltd. – Subhanu Saxena, Managing Director & Global CEO
Glenmark – Glenn Saldanha, Chairman and Managing Director
GSK – Hasit. B. Joshipura, Managing Director
IBEF – Aparna Dutt Sharma, CEO
Lupin – Ramesh Swaminathan, CEO
Ministry of Commerce & Industry, Government of India – Shri Sudhanshu Pandey, Joint Secretary
Pharmexcil – Dr. P V Appaji, Director General
Piramal Enterprises Ltd. – Vivek Sharma, CEO Pharma Solutions & Critical Care
Sun Pharma – Abhay Gandhi, CEO India
Supriya Lifescience – Satish W. Wagh, Chairman and Managing Director

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

Québec and Atlantic Canada Mining 2025

Québec and Atlantic Canada have traversed 2025 in an enviable position. Strong gold prices have buoyed balance sheets and investor sentiment, while global demand for critical minerals keeps the region firmly on the radar of international markets. At the same time, the provinces’ depth of mining expertise – from AI-driven exploration to advanced drilling, blasting, and geophysics – ensures that technological advantage is firmly on their side.

MORE PREVIOUSLY PUBLISHED

MACIG

"Our jurisdictional diversification is certainly a defining characteristic of Thor, but so is the fact that our projects are also diversified by stage of development."

SUBSCRIBE TO OUR NEWSLETTER